DexCom PT Raised to $31.00 at Raymond James (DXCM)
Equities researchers at Raymond James hoisted their target price on shares of DexCom (NYSE:DXCM) from $26.00 to $31.00 in a research report issued on Monday, American Banking and Market News reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price objective points to a potential upside of 6.75% from the stock’s previous close.
A number of other analysts have also recently weighed in on DXCM. Analysts at JPMorgan Chase & Co. initiated coverage on shares of DexCom in a research note to investors on Friday, September 13th. They set an “overweight” rating and a $32.00 price target on the stock. Separately, analysts at Wedbush raised their price target on shares of DexCom from $18.00 to $31.00 in a research note to investors on Tuesday, August 13th. They now have an “outperform” rating on the stock. Finally, analysts at Feltl & Co. raised their price target on shares of DexCom from $16.50 to $18.25 in a research note to investors on Monday, August 12th. They now have a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $24.92.
DexCom (NYSE:DXCM) traded up 5.79% on Monday, hitting $29.04. The stock had a trading volume of 699,938 shares. DexCom has a 1-year low of $12.03 and a 1-year high of $29.24. The stock has a 50-day moving average of $27.57 and a 200-day moving average of $22.48. The company’s market cap is $2.073 billion.
DexCom, Inc is a medical device company. The Company focuses on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.